Explainer: Myriad Genetics and BRCA1 Patent Ruling

You have almost certainly heard the news by now: Queensland cancer survivor Yvonne D’Arcy has won an extensive battle against US biotech company Myriad Genetics. The Australian High Court ruled that the BRCA1 genetic mutation patent could not be owned by Myriad or any other company, allowing breast cancer sufferers access to diagnostic tests without exorbitant fees from private companies.

Lung disorder genetic link identified

Why do some smokers avoid lung disease and some non-smokers develop it? Researchers in the UK have found the genetic link to cardio-pulmonary disorders (COPD) incuding bronchitis and emphysema which indicates the way lungs grow and respond to injury.

Aspirin claims another title: Cancer Fighter

New research presented at the 2015 European Cancer Congress has found that in a study of cancer patients in the Netherlands, a daily dose of aspirin can improve the life expectancy of those experiencing cancers of  the gastrointestinal tract.

Improving burn care across the nation

The PCEHR arrives in the last chance saloon

Nursing Home Funding

Aged-care funding creates dependency and lowers well-being of residents

Breast Imaging – The way forward

Emergency Care in Papua New Guinea - A Volunteer’s Perspective

Identification and risk assessment of hazardous medicines

Key Issues with IV Connectors

Advertorial

The Big Deal About Biologics

Dr Deborah Gleeson is a lecturer in public health at La Trobe University. Her research focuses on the impact of trade agreements on healthcare and public health policy. She is convener of the Political Economy of Health Special Interest Group of the Public Health Association of Australia (PHAA), and represents PHAA on matters related to trade agreements, including the TPP.

Evidence-based training helps meet IPC targets

Getting armed for battle – The perioperative challenge

Providing cancer care to Springfield

Clinical trials of Cancer Therapy in private medical practice in Australia